A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease
about
What are biomarkers?Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registryFollow up of patients with chronic granulomatous disease diagnosed since 1990Prevention of infections during primary immunodeficiencyChronic granulomatous diseaseLiver-directed gamma interferon gene delivery in chronic hepatitis C.Residual NADPH oxidase and survival in chronic granulomatous diseaseClinical implications of interferon-γ genetic and epigenetic variantsAspergillus fumigatus and aspergillosisClinical Features and Genetic Analysis of 48 Patients with Chronic Granulomatous Disease in a Single Center Study from Shanghai, China (2005-2015): New Studies and a Literature Review.Innate immunity to Aspergillus species.Bayesian imperfect information analysis for clinical recurrent data.Innate immune deficiency of extremely premature neonates can be reversed by interferon-γ.Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease.Chronic Granulomatous Disease Presenting as Aspergillus Fumigatus Pneumonia in a Previously Healthy Young Woman.IFN-γ stimulates autophagy-mediated clearance of Burkholderia cenocepacia in human cystic fibrosis macrophagesGamma interferon treatment of patients with chronic granulomatous disease is associated with augmented production of nitric oxide by polymorphonuclear neutrophils.USIDNET: a strategy to build a community of clinical immunologists.Aspergillus infections in transplant recipients.Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndromeEpic Immune Battles of History: Neutrophils vs. Staphylococcus aureus.Cytokines in infectious diseases.Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy.Xanthine oxidase contributes to host defense against Burkholderia cepacia in the p47(phox-/-) mouse model of chronic granulomatous disease.Type 1/Type 2 immunity in infectious diseases.Nocardia infection in chronic granulomatous disease.Tryptophan/kynurenine metabolism in human leukocytes is independent of superoxide and is fully maintained in chronic granulomatous disease.Neutrophil disorders and their management.P67-phox (NCF2) lacking exons 11 and 12 is functionally active and leads to an extremely late diagnosis of chronic granulomatous disease (CGD)PEGylation improves the pharmacokinetic properties and ability of interferon gamma to inhibit growth of a human tumor xenograft in athymic mice.Adjunctive immune therapy for fungal infections.Treatment options in Invasive Aspergillosis.Neutrophils and mononuclear cells from patients with chronic granulomatous disease release nitric oxide.Treatment of disseminated mycobacterial infection with high-dose IFN-γ in a patient with IL-12Rβ1 deficiency.Gastrointestinal and hepatic manifestations of primary immune deficiency diseases.Phagocyte NADPH oxidase, but not inducible nitric oxide synthase, is essential for early control of Burkholderia cepacia and chromobacterium violaceum infection in micePractice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Penicillium piceum infection: diagnosis and successful treatment in chronic granulomatous disease.Chronic granulomatous disease: lessons from a rare disorder.Cytokine modulation in sepsis and septic shock.
P2860
Q24613362-B2EC04F2-7BFE-416D-9FBC-5B0E74546591Q24655272-E66DAF75-55F0-4D45-9473-E57E23DF3385Q24681802-AFF4CB29-ACEC-4A36-9C18-E157F389F315Q27008430-6EEF6334-BAE2-47C5-80D9-B541B23195B6Q27009322-303A3A9F-47F3-4FE1-9D3B-9D733DF6A320Q27472673-475032C2-4F69-4A17-94EC-2E2996E0EEF9Q28301969-BF25DFD5-AFEF-46DC-BE90-14069ECEF6CAQ28383437-9ECA4AE6-35DE-4608-B0C1-7CE6A794406DQ29617908-9CE9A2A5-AEF3-47F3-BFF5-895F3585171FQ30235499-5C67FB91-1D85-4981-B42B-2C159557E5BEQ30434628-C60A6830-44A8-41AB-A686-EF3EC7182705Q30883102-936C6ED2-EA20-40FF-8985-02D1E383F310Q31051254-193D031B-AFBE-460C-8885-5833CA129A40Q33379412-A074216B-70C8-4FEC-B3D4-35865092F565Q33553834-E416B1BA-243E-40B4-80E4-71EE5E49976DQ33568014-9E828260-D704-4C84-B563-C9BEF54C6983Q33637370-6EC95115-CA30-4A28-9081-469EDEF98AD2Q33716493-177C8FEE-2E27-4AF8-A7EC-92354275C4EBQ33719294-F800B081-292E-494E-ABC6-C2C9E4CDD159Q33849472-F6637390-1E4F-4EC5-A628-8CD8EE341807Q33854487-B65F1EE9-84C6-45C2-8E50-217BEE80043FQ33930520-E6561028-2CE2-4CF6-A111-BD47646A977AQ33973488-E1E88C1A-BFA4-41F2-AA9D-B6AB027697F8Q34004078-6B553662-4BDA-455A-B4B5-A319996C1926Q34105379-44758DF9-DFF4-49D5-B8A2-DE0DFE0D25D8Q34141669-D21E51F7-39A8-4910-81C5-F26884E22A3FQ34163016-A263770D-C17F-4157-88FE-35E074646BADQ34197117-917EEF32-0181-4C7B-985D-77D5374405D8Q34238532-73A98628-1041-49A8-813A-4CE1FD9AF57CQ34294045-657C0E8D-A8C0-4CFF-9691-44B4FAB75FD9Q34350401-4E8A8659-2690-4BB8-B376-957CB359775CQ34357504-6111B877-3F3B-440E-B3D9-CBF32EBEA6E8Q34404279-608A7054-B189-4189-BC12-0B0578287847Q34460558-588209B5-7CB5-4852-B298-7A739A739698Q34469023-FBCA8F81-4ACC-426C-99DA-5069EDAF625CQ34521507-2415E8D3-DA87-4339-95A5-3661321BBDE1Q34532546-C316C784-BB1E-40CB-A6A1-F65730FCAF37Q34584769-DD8301B4-F2B5-405D-AF7A-0A735407C776Q34644316-81CAE7A0-C0BB-49E7-A593-4D8A9A696C08Q34768553-E3142310-4C43-476F-8201-FA879EDF7EA8
P2860
A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease
description
im Februar 1991 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 1991
@uk
name
A Controlled Trial of Interfer ...... Chronic Granulomatous Disease
@en
A Controlled Trial of Interfer ...... Chronic Granulomatous Disease
@nl
type
label
A Controlled Trial of Interfer ...... Chronic Granulomatous Disease
@en
A Controlled Trial of Interfer ...... Chronic Granulomatous Disease
@nl
prefLabel
A Controlled Trial of Interfer ...... Chronic Granulomatous Disease
@en
A Controlled Trial of Interfer ...... Chronic Granulomatous Disease
@nl
P1476
A Controlled Trial of Interfer ...... Chronic Granulomatous Disease
@en
P304
P356
10.1056/NEJM199102213240801
P407
P577
1991-02-21T00:00:00Z